INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against BioAge Labs, Inc. (NASDAQ: BIOA); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. and certain executives for alleged violations of federal securities laws related to the company's IPO, following significant stock price decline after safety concerns emerged regarding its lead product candidate, azelaprag [1][4][5]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities who purchased BioAge common stock linked to the IPO registration statement dated September 26, 2024 [1]. - Investors have until March 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1]. - The lawsuit alleges that BioAge and its executives made false and misleading statements regarding the safety of azelaprag during the IPO process [4]. Group 2: Company Background - BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases by targeting human aging biology [3]. - The main product candidate, azelaprag, is designed to treat obesity by targeting the apelin receptor to mimic the biological benefits of exercise [3]. Group 3: Stock Performance - Following the announcement of safety concerns related to azelaprag, BioAge's stock price fell by $15.44 per share, a decline of over 76% [5]. - At the time the lawsuit was filed, BioAge's stock was trading at approximately $5.36 per share, down from the IPO price of $18 per share [5].